Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease

Tropical Medicine and International Health

Volumn 18, Issue 3, 2013, Pages 313-327

  Aneni, Ehimen C ^a,b   Hamer, Davidson H ^a,c,d   Gill, Christopher J ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Zambia Centre for Applied Health Research and Development   (Zambia)

Author keywords

Hydroxyurea; Malaria; Malaria chemoprophylaxis; Plasmodium falciparum; Sickle cell disease; Sub Saharan Africa

Indexed keywords

BENZATHINE PENICILLIN; CHLOROQUINE; HEMOGLOBIN F; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; MEFLOQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE;

ANEMIA; DRUG RESISTANCE; EMERGENCE; HEMOGLOBIN; INFECTIVITY; LITERATURE REVIEW; MALARIA; MORBIDITY; MORTALITY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLOOD TRANSFUSION; CHEMOPROPHYLAXIS; DRUG TOLERABILITY; ERYTHROCYTE; HUMAN; MALARIA; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AFRICA SOUTH OF THE SAHARA; ANEMIA, SICKLE CELL; ANTIMALARIALS; ANTISICKLING AGENTS; COMORBIDITY; DRUG RESISTANCE; ENDEMIC DISEASES; HUMANS; HYDROXYUREA; MALARIA; MALARIA, FALCIPARUM; PLASMODIUM;

SUB-SAHARAN AFRICA;

PLASMODIUM FALCIPARUM;

EID: 84873996697     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12056     Document Type: Review

References (71)

1. Aidoo M, Terlouw DJ, Kolczak MS et al. (2002) Protective effects of the sickle cell gene against malaria morbidity and mortality. The Lancet 359, 1311-1312.
2. Alexy T, Sangkatumvong S, Connes P et al. (2010) Sickle cell disease: selected aspects of pathophysiology. Clinical Hemorheology and Microcirculation 44, 155-166.
3. Angastiniotis M & Modell B (1998) Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences 850, 251-269.
4. Asante KP, Abdulla S, Agnandji S et al. (2011) Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. The Lancet Infectious Diseases 11, 741-749.
5. Ayi K, Turrini F, Piga A & Arese P (2004) Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 104, 3364-3371.
6. Bach O, Baier M, Pullwitt A et al. (2005) Falciparum malaria after splenectomy: a prospective controlled study of 33 previously splenectomized Malawian adults. Transactions of the Royal Society of Tropical Medicine and Hygiene 99, 861-867.
7. Boone KE & Watters DA (1995) The incidence of malaria after splenectomy in Papua New Guinea. BMJ 311, 1273.1.
8. Bronzan RN, Taylor TE, Mwenechanya J et al. (2007) Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. Journal of Infectious Diseases 195, 895-904.
9. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R & Lapoumeroulie C (2003) Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal 3, 215-226.
10. Buffet PA, Safeukui I, Deplaine G et al. (2011) The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117, 381-392.
11. Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine 337, 762-769.
12. Centers for Disease Control and Prevention (2011) Sickle cell disease, data and statistics - NCBDDD [WWW Document]. http://www.cdc.gov/NCBDDD/sicklecell/data.html#references.
13. Chotivanich K, Udomsangpetch R, McGready R et al. (2002) Central role of the spleen in malaria parasite clearance. Journal of Infectious Diseases 185, 1538-1541.
14. Claster S & Vichinsky E (1996) First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 88, 1951-1953.
15. Cunnington AJ, de Souza JB, Walther M & Riley EM (2012) Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nature Medicine 18, 120-127.
16. Diop S, Soudré F, Seck M et al. (2011) Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial. Annals of Hematology 90, 23-27.
17. Dover GJ & Charache S (1989) Chemotherapy and hemoglobin F synthesis in sickle cell disease. Annals of the New York Academy of Sciences 565, 222-226.
18. Eke FU & Anochie I (2003) Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study. Current Therapeutic Research, Clinical and Experimental 64, 616-625.
19. Engwerda CR, Beattie L & Amante FH (2005) The importance of the spleen in malaria. Trends in Parasitology 21, 75-80.
20. Fleming AF (1989) The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Reviews 3, 18-28.
21. Guerin PJ, Olliaro P, Nosten F et al. (2002) Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. The Lancet Infectious Diseases 2, 564-573.
22. Hankins JS, Ware RE, Rogers ZR et al. (2005) Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106, 2269-2275.
23. Hankins JS, Helton KJ, McCarville MB, Li C, Wang WC & Ware RE (2008) Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood & Cancer 50, 293-297.
24. Holland KP, Elford HL, Bracchi V, Annis CG, Schuster SM & Chakrabarti D (1998) Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives. Antimicrobial Agents and Chemotherapy 42, 2456-2458.
25. Ingram VM (1956) A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 178, 792-794.
26. Johnston RB Jr, Newman SL & Struth AG (1975) Increased susceptibility to infection in sickle cell disease: defects of opsonization and of splenic function. Birth Defects Original Article Series 11, 322-327.
27. Kennedy JR (2010) An autologous falciparum vaccine using the erythrocyte's band 3 molecule. Medical Hypotheses 74, 503-504.
28. Komba AN, Makani J, Sadarangani M, Ajala-Agbo T et al. (2009) Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. Clinical Infectious Diseases 49, 216-222.
29. Konotey-Ahulu FI (1971) Malaria and sickle-cell disease. British Medical Journal 2, 710-711.
30. Kotila R, Okesola A & Makanjuola O (2007) Asymptomatic malaria parasitaemia in sickle-cell disease patients: how effective is chemoprophylaxis? Journal of Vector Borne Diseases 44, 52-55.
31. Lewthwaite CJ (1962) A trial of chemoprophylaxis in Sickle-Cell anaemia. East African Medical Journal 39, 196-199.
32. Mackenzie G, Ceesay SJ, Hill PC et al. (2010) A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS ONE 5, e10568.
33. Makani J, Komba AN, Cox SE et al. (2010) Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood 115, 215-220.
34. McAuley CF, Webb C, Makani J et al. (2010) High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 116, 1663-1668.
35. Mellouli F & Bejaoui M (2008) L'utilisation de l'hydroxyurée dans les formes sévères de la drépanocytose : étude de 47 cas pédiatriques tunisiens. Archives de Pédiatrie 15, 24-28.
36. Modell B & Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 86, 480-487.
37. Moher D, Schulz KF & Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of randomized trials. BMC medical Research Methodology 1, 2.
38. Murray CJ, Rosenfeld LC, Lim SS et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. The Lancet 379, 413-431.
39. Nakibuuka V, Ndeezi G, Nakiboneka D, Ndugwa C & Tumwine J (2009) Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. Malaria Journal 8, 237.
40. Olotu A, Lusingu J, Leach A et al. (2011) Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet Infectious Diseases 11, 102-109.
41. Onwubalili JK (1983) Sickle cell disease and infection. Journal of Infection 7, 2-20.
42. Pasvol G, Weatherall DJ, Wilson RJ, Smith DH & Gilles HM (1976) Fetal haemoglobin and malaria. Lancet 1, 1269-1272.
43. Pasvol G, Weatherall DJ & Wilson RJ (1977) Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum. Nature 270, 171-173.
44. Pauling L, Itano HA, Singer SJ & Wells IC (1949) Sickle cell anemia, a molecular disease. Science 110, 543-548.
45. Piel FB, Patil AP, Howes RE et al. (2010) Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nature Communications 1, 104.
46. Pino P, Taoufiq Z, Brun M et al. (2006) Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models. Parasite Immunology 28, 675-680.
47. Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. New England Journal of Medicine 358, 1362-1369.
48. Rees DC, Williams TN & Gladwin MT (2010) Sickle-cell disease. The Lancet 376, 2018-2031.
49. Santos A, Pinheiro V, Anjos C et al. (2002) Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. European Journal of Nuclear Medicine and Molecular Imaging 29, 536-541.
50. Scott JAG, Berkley JA, Mwangi I et al. (2011) Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 378, 1316-1323.
51. Sebastiani P, Solovieff N, Hartley SW et al. (2010) Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. American Journal of Hematology 85, 29-35.
52. Serjeant GR (1989) Geography and the clinical picture of sickle cell disease. Annals of the New York Academy of Sciences 565, 109-119.
53. Shear HL, Grinberg L, Gilman J et al. (1998) Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 92, 2520-2526.
54. Steinberg MH (2005) Predicting clinical severity in sickle cell anaemia. British Journal of Haematology 129, 465-481.
55. Steinberg MH, Barton F, Castro O et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. JAMA: The Journal of the American Medical Association 289, 1645-1651.
56. Stuart MJ & Nagel RL (2004) Sickle-cell disease. The Lancet 364, 1343-1360.
57. Thein SL (2011) Genetic modifiers of sickle cell disease. Hemoglobin 35, 589-606.
58. Thera MA, Doumbo OK, Coulibaly D et al. (2011) A field trial to assess a blood-stage malaria vaccine. New England Journal of Medicine 365, 1004-1013.
59. Trompeter S & Roberts I (2009) Haemoglobin F modulation in childhood sickle cell disease. British Journal of Haematology 144, 308-316.
60. Uzoegwu PN & Onwurah AE (2003) Prevalence of haemoglobinopathy and malaria diseases in the population of Old Aguata Division, Anambra State, Nigeria. Biokemistri 15, 57-66.
61. Wang WC, Ware RE, Miller ST et al. (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). The Lancet 377, 1663-1672.
62. Warley MA, Hamilton PJS, Marsden PD, Brown RE, Merselis JG & Wilks N (1965) Chemoprophylaxis of homozygous sicklers with antimalarials and long-acting penicillin. The British Medical Journal 2, 86-88.
63. Were T, Davenport GC, Hittner JB et al. (2011) Bacteremia in Kenyan children presenting with malaria. Journal of Clinical Microbiology 49, 671-676.
64. White JG & Heagan B (1970) The fine structure of cell-free sickled hemoglobin. American Journal of Pathology 58, 1-17.
65. WHO African Region (2010) Sickle-cell Disease: A Strategy for the WHO African Region WHO African Region, Malabo, Equitorial Guinea.
66. Williams TN, Mwangi TW, Wambua S et al. (2005) Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. Journal of Infectious Diseases 192, 178-186.
67. Wilson RJ, Pasvol G & Weatherall DJ (1977) Invasion and growth of Plasmodium falciparum in different types of human erythrocyte. Bulletin of the World Health Organization 55, 179-186.
68. World Health Organization (2010) WHO Global report on antimalarial efficacy and drug resistance: 2000-2010 World Health Organization, Switzerland.
69. World Health Organization (2011) World Malaria Report 2011 World Health Organization, Switzerland.
70. Young MD & Moore DV (1961) Chloroquine resistance in Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 10, 317-320.
71. Zimmerman SA, Schultz WH, Davis JS et al. (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103, 2039-2045.